Sweden · Delayed Price · Currency is SEK Cereno Scientific AB Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing its lead HDAC inhibitor into a global phase IIb trial for pulmonary arterial hypertension, targeting disease modification and remission. With strong clinical progress, regulatory support, and a multi-billion dollar market opportunity, strategic partnerships and platform expansion are key priorities this year.
Fiscal Year 2025
-
Epigenetic drug programs for rare cardiovascular and lung diseases are advancing, with two Phase 2 trials set to start next year. FDA Fast Track status, global partnerships, and strong investor growth support ongoing development and potential pharma deals.
-
CS1 demonstrated safety and promising efficacy in a phase 2A PAH trial, with improvements in risk scores, heart function, and quality of life. Ongoing studies and imaging aim to confirm disease-modifying effects, with a phase 2B trial and further regulatory discussions planned.
Fiscal Year 2024
-
Focused on rare cardiovascular and pulmonary diseases, the company reported strong phase II-A results for its lead PAH program, secured FDA expanded access, and expects key regulatory milestones and long-term data in H1 next year. Operations are funded into 2026.
-
The company is advancing a rare disease-focused portfolio with CS1 showing strong safety and efficacy signals in PH, CS014 targeting IPF with a novel HDAC inhibitor, and CS585 progressing toward clinical trials for rare thrombosis. Strategic collaborations, innovative imaging, and orphan drug incentives support rapid development and commercial potential.
-
The phase IIa trial of CS1 in pulmonary arterial hypertension met its primary safety endpoint and showed promising efficacy signals, including improvements in REVEAL Risk Score, functional class, and hemodynamics. Preclinical and clinical data support CS1's potential to reverse vascular remodeling, and regulatory engagement for a pivotal trial is underway.